Pharmacoeconomic analysis of dapagliflozin in patients with chronic kidney disease and type 2 diabetes in the Russian Federation

• Main Authors: Sergey V. Nedogoda (Author), Minara S. Shamkhalova (Author), Alla S. Salasyuk (Author), Viktoriya O. Lutova (Author), Irina N. Barykina (Author), Ekaterina A. Popova (Author)
• Format: Book
• Published: LLC "MEDIAFORMAT", 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background. The economic costs associated with chronic kidney disease (CKD) are a significant burden on the health care system. The use of dapagliflozin is a breakthrough strategy in the management of patients with CKD and type 2 diabetes mellitus (T2DM) to slow the progression of the disease and re...